Search hospitals > Nevada > Las Vegas
Comprehensive Cancer Centers of Nevada-Summerlin
Claim this profileLas Vegas, Nevada 89144
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Tumors
192 reported clinical trials
3 medical researchers
Summary
Comprehensive Cancer Centers of Nevada-Summerlin is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Tumors and other specialties. Comprehensive Cancer Centers of Nevada-Summerlin is involved with conducting 192 clinical trials across 355 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Henry Igid, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
148 reported clinical trials
226 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation7 years of reported clinical research
Expert in Tumors
Expert in Leukemia
52 reported clinical trials
109 drugs studied
Henry Igid, MDComprehensive Cancer Centers of Nevada - Town Center3 years of reported clinical research
Studies B-Cell Lymphoma
Studies Diffuse Large B-Cell Lymphoma
1 reported clinical trial
7 drugs studied
Clinical Trials running at Comprehensive Cancer Centers of Nevada-Summerlin
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Gastric Cancer
Renal Cell Carcinoma
Esophageal Cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Comprehensive Cancer Centers of Nevada-Summerlin?
Comprehensive Cancer Centers of Nevada-Summerlin is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Adenocarcinoma, Tumors and other specialties. Comprehensive Cancer Centers of Nevada-Summerlin is involved with conducting 192 clinical trials across 355 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Henry Igid, MD.